June 16th, 2025 – Shanghai — Hasten Biopharmaceutical Co., Ltd. (“Hasten”) announced today the completion of Market Authorization Transfers (MAT) for 11 major pharmaceutical products across several key Asia-Pacific markets, including Malaysia, Singapore, Philippines, Hong Kong S.A.R. (China), etc.. The transfers were carried out by its affiliated entity, Hasten Biopharmaceutics (Asia) Co., Ltd., during the first half of 2025. This accomplishment marks a strategic leap forward in Hasten’s regional expansion, reinforcing its commitments to building a robust, patient-centric commercial ecosystem in Asia-Pacific and bringing high-quality products and solutions to more patients.

The transferred products are well-established in the treatment of chronic diseases, particularly in the cardiovascular and diabetes segments, including Actos^®, Actosmet^®, Blopress^®, Blopress Plus^®, Nesina^®, Nesinamet^®, Ubretid^®, Unisia^®, Albothyl^®, Edarbi^® and Oseni^®. Hasten will fully leverage its expertise in regulatory filing, manufacturing transfer and marketing strategies across the Asia-Pacific region, to provide professional services to facilitate global biopharmaceutical partners during their localization operation and commercialization, enabling achieving their Asia-Pacific goals jointly. 

Mr. Honggang Feng, Chairman and CEO of Hasten, stated: "The successful MAT transfers of multiple chronic disease products have significantly expanded Hasten’s portfolio in the Asia-Pacific region. This marks a key milestone in our globalization journey and reinforces our commitments to delivering high-quality medicines and therapeutic solutions tailored to the evolving needs of patients and healthcare systems across Asia-Pacific. Together with our regional partners, we will accelerate the value transformation of high-quality products, broaden our global footprint, and co-create a healthcare ecosystem that benefits patients worldwide."

Ms. Peggy Fung, Vice President and Head of Asia-Pacific Commercial at Hasten, added: "Achieving MAT transfers across multiple markets in such a short time demonstrates Hasten’s strong alignment with international standards in areas such as regulatory, supply chain, quality control and commercialization management. This also reflects our growing influence in the Asia-Pacific area. We will continue to leverage our experience in commercializing mature products, together with multi collaboration matrix that includes supplier, distributors and industry partners, etc., to provide high-quality and accessible treatments to more patients across the Asia-Pacific region."

As an innovative biopharmaceutical company, Hasten strategically focuses on high-demand therapeutics such as chronic diseases and acute care areas and continuously driving impactful growth. In addition to synergizing alliances with strategic partnerships within mainland China, Hasten diversified its regional expansion since having acquired the commercial rights to a portfolio of branded products across eight Asia-Pacific countries and regions in 2024 and has been supported by the establishment of a dedicated highly experienced regional team to drive strategic growth. These workable overseas initiatives have not only validated Hasten’s globalization strategy but also created replicable business models that will ensure sustainable growth.

Rooted in China, thinking globally. Hasten is actively advancing more transferring across Asia-Pacific and expand the life cycle of the product pipeline, which will strengthen the company’s Pan-Asia-Pacific commercial footprint, expand patient access, and strength the company’s potential as a healthcare leader with world-class commercialization capabilities.

About Hasten

Hasten Biopharmaceutical Co., Ltd., (Hasten), which integrates R&D, production and commercial promotion and covers the whole industrial chain, was established in 2020. Hasten is committed to building a premier commercial platform and becoming a leader in the healthcare industry. Adhering to the patient-centric philosophy, Hasten will fully leverage sustainable, self-sustaining commercialization capabilities to accelerate the value realization of high-quality products, provide innovative therapeutic solutions to benefit patients and create social value.

For more information, please view website: m.shaoniangong.cn 

Linked-in：Hasten